✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Marksans Pharma Ltd.

MARKSANS

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹10,178 Cr.
P/E
26.74

Marksans Pharma Ltd.

  • Marksans Pharma
  • Procter&Gamble Healt
  • Strides Pharma Scien
  • TJI Pharma - Small Cap
FAQs on Marksans Pharma Ltd. Shareprice

Marksans Pharma has given lower returns compared to its competitors.
Marksans Pharma has grown at ~8.09% over the last 10yrs while peers have grown at a median rate of 9.46%

Yes, Marksans Pharma is expensive.
Latest PE of Marksans Pharma is 27.12, while 3 year average PE is 18.96.
Also latest EV/EBITDA of Marksans Pharma is 18.24 while 3yr average is 12.46.

View FAQ's On Business
Growth Table
  • Marksans Pharma Ltd.
  • Procter&Gamble Healt
  • Strides Pharma Scien
Balance Sheet
  • Marksans Pharma Ltd.
  • Procter&Gamble Healt
  • Strides Pharma Scien
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Marksans Pharma Ltd.
  • Procter&Gamble Healt
  • Strides Pharma Scien
Cash Flow
  • Marksans Pharma Ltd.
  • Procter&Gamble Healt
  • Strides Pharma Scien
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Marksans Pharma Ltd.
  • Procter&Gamble Healt
  • Strides Pharma Scien
Quarterly Results
  • Marksans Pharma Ltd.
  • Procter&Gamble Healt
  • Strides Pharma Scien
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Marksans Pharma Ltd. Financials

Balance sheet of Marksans Pharma is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Marksans Pharma is decreasing.
Latest net debt of Marksans Pharma is -₹1,385.3 Crs as of Mar-25.
This is less than Mar-24 when it was -₹1,318.02 Crs.

Yes, profit is increasing.
The profit of Marksans Pharma is ₹381 Crs for Mar 2025, ₹314 Crs for Mar 2024 and ₹266 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Marksans Pharma latest dividend payout ratio is 9.53% and 3yr average dividend payout ratio is 8.9%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Inventory

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech